Primary Hyperoxaluria Type 1 (PH1)

International Pediatric Nephrology Association (IPNA) 2025

Congress Details

calander19-23 February, 2025 | SA

locationCape Town, South Africa

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to lumasiran. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Oral

Congress Materials

IPNA
icon Presentation Type
Presentation
location icon Location
Cape Town, South Africa
icon Title
Lumasiran for Primary Hyperoxaluria Type 1: Analysis of Urinary Oxalate and Estimated Glomerular Filtration Rate Over Time in Patients by Genotype

Associated Materials

American-Society-of-Nephrology-Houston-TX-Mobile

Primary Hyperoxaluria Type 1 (PH1)

American Society of Nephrology (ASN) 2025

6-9 November, 2025 TX

View Details
Preparation Date
March 2026
Job Code
MB-UK-00086
European-Society-for-Paediatric-Nephrology,Athens,Greece-Mobile

Primary Hyperoxaluria Type 1 (PH1)

European Society for Paediatric Nephrology (ESPN) 2025

15-18 October, 2025 Greece

View Details
Preparation Date
March 2026
Job Code
MB-UK-00085
International Paediatric Transplant Association (IPTA) 2025 Congress, Germany

Primary Hyperoxaluria Type 1 (PH1)

International Paediatric Transplant Association (IPTA) 2025

18-21 September 2025 Germany

View Details
Preparation Date
March 2026
Job Code
MB-UK-00088
European Society for Paediatric Urology (ESPU) 2025 Congress, Austria

Primary Hyperoxaluria Type 1 (PH1)

European Society for Paediatric Urology (ESPU) 2025

3-6 September 2025 AUSTRIA

View Details
Preparation Date
March 2026
Job Code
MB-UK-00089
European Society for Paediatric Urology (ESPU) 2025 Congress, Austria

Primary Hyperoxaluria Type 1 (PH1)

European Renal Association (ERA) 2025

4-7 June 2025 Austria

View Details
Preparation Date
March 2026
Job Code
MB-UK-00091

Primary Hyperoxaluria Type 1 (PH1)

Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-Up of the Phase 3 Illuminate-C Trial

American Journal of Kidney Diseases

Author(s)

Anne-Laure Sellier-Leclerc, Daniella Magen, Hadas Shasha-Lavsky, et al

March 2025

Preparation Date
March 2026
Job Code
MB-UK-00171
Preparation Date
March 2026
Job Code
MB-UK-00093